Informa's Cell Therapy Manufacturing & Gene Therapy Congress had been scheduled for December 2015 but was postponed until February 2016 due to the Paris terrorist attrocities. Despite this, the industry flocked to the Sheraton, Brussels Airport to discuss the problems and solutions to manufacturing cell and gene therapies.
And Biopharma-Reporter was there too to bring you the best of what the congress had to offer
23-Feb-2016 - Scaling-up without expanding its manufacturing footprint was key in selecting Pall's Xpansion bioreactor, says UCL which is looking to create “the world’s largest therapeutic cell bank.”
19-Feb-2016 - The shelf life of a cell therapy product is crucial in determining a firm’s manufacturing strategy according to the makers of the first approved stem-cell based drug.
10-Feb-2016 - Reliance on third-party technologies is leaving T-Cell drug developers vulnerable and has driven the larger players to invest in their own platforms, say experts.
05-Feb-2016 - Bovine serum remains the gold standard in cell culture supplements despite its many flaws, says Cook Regentec.
04-Feb-2016 - Cell therapy development and production will not be sustainable unless there is a vendor-led shift to automated processes, said experts in Brussels yesterday.
03-Feb-2016 - [View the story "If it's Wednesday this must be the Cell therapy manufacturing and gene therapy congress" on Storify]